This site has been created solely for the purpose of providing information about services available from Richmond Pharmacology. The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.
Mission Statement
Our Mission Statement guides our employees, volunteers and stakeholders and outlines our goals and objectives as an organisation.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
